Brokerages expect Bellus Health Inc. (NYSE:BLU) to announce $10,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Bellus Health’s earnings. Bellus Health also reported sales of $10,000.00 during the same quarter last year. The firm is expected to issue its next quarterly earnings report on Wednesday, November 13th.

According to Zacks, analysts expect that Bellus Health will report full year sales of $30,000.00 for the current financial year, with estimates ranging from $20,000.00 to $30,000.00. For the next financial year, analysts forecast that the business will report sales of $960,000.00, with estimates ranging from $20,000.00 to $2.84 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Bellus Health.

Bellus Health (NYSE:BLU) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.01 million for the quarter.

Several equities research analysts have recently issued reports on the stock. JBL Advisors assumed coverage on shares of Bellus Health in a research note on Monday, September 30th. They issued a “buy” rating on the stock. Guggenheim initiated coverage on Bellus Health in a report on Monday, September 30th. They issued a “buy” rating and a $12.00 price target for the company. Cowen initiated coverage on Bellus Health in a report on Monday, September 30th. They issued an “outperform” rating for the company. Jefferies Financial Group initiated coverage on Bellus Health in a report on Monday, September 30th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Bloom Burton reaffirmed a “buy” rating on shares of Bellus Health in a report on Friday, September 6th. Five analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $16.00.

Shares of NYSE BLU opened at $6.24 on Monday. Bellus Health has a 52 week low of $1.76 and a 52 week high of $9.36.

About Bellus Health

BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.

Featured Story: Oversold

Get a free copy of the Zacks research report on Bellus Health (BLU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellus Health (NYSE:BLU)

Receive News & Ratings for Bellus Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health and related companies with MarketBeat.com's FREE daily email newsletter.